Wyniki wyszukiwania - Biblioteka Nauki

1

Pazopanib in clear cell sarcoma therapy

100%

Kryszczyszyn-Musialik K. , Słomian G.

OncoReview

|

2018

|

tom 8

|

nr 1

24-27

EN

Clear cell sarcoma (CCS) is a rare soft-tissue sarcoma and is characterized by a translocation t(12;22) (q13;q12). Because of some similarities to maligned melanoma it is called melanoma of soft parts. CCS has characteristic clinical features. It is commonly reported in young adults as slowly growing tumor followed by aggressive course. Its features are: regional lymph node spread and tendency for local recurrence and a propensity for pulmonary metastasis. Metastatic CCS is a very aggressive disease with pure prognosis. Conventional chemotherapy has little role to play in the management of CCS. The article presents the case of a patient with metastatic CCS with massive lung dissemination, metastatic in liver, left adrenal, pelvis and superficial soft tissue. In patient pazopanib therapy resulted in nine-month control of the disease.

2

Comprehensive Geriatric Assessment (CGA) in qualification for palliative chemotherapy

80%

Kryszczyszyn-Musialik K. , Słomian G. , Jośko-Ochojska J.

OncoReview

|

2019

|

tom 9

|

nr 3

64-67

EN

More than a half of new cancer cases affects elderly people. The number of patients in that group is constantly raising. Geriatric patients with cancer are very ununiform group with their biological age, comorbidities and conditions. The risk of the treatment’s toxicity in that group is increased due to loss of organ reserves. Based not only on metrical age or performance status but using precise assessment aids with choosing proper treatment this lowers the complication rate. Comprehensive Geriatric Assessment (CGA) is a multidimensional tool that helps assess elderly patients including daily living, physical status, cognitive functions, depression, nutrition and comorbidities. The following describes utility of CGA in 77-year-old male with colon cancer being qualified for palliative chemotherapy

3

The role of histopathological examination, therapeutic difficulties and thromboembolism treatment during palliative chemotherapy in patient with antithrombin deficiency, colon cancer and endometrial cancer

80%

Kryszczyszyn-Musialik K. , Dolczak L. , Słomian G.

OncoReview

|

2017

|

tom 7

|

nr 1

28-31

EN

Palliative chemotherapy in patients with thrombophilia is a challenge for clinical oncologists. On one hand the optimal treatment should be very safe for patient, on the other hand – as effective as possible. That therapy is also connected with proper thromboprophylaxis. The incidence of multiple cancers is a serious problem of modern oncology. In patients whose medical history includes two or more cancers, it is essential to obtain histopathological diagnosis before the administration of treatment of disseminated disease. It allows to avoid improper therapy which is often toxic. The article presents the case of a patient with antithrombin deficiency and two cancers in medical history: colon cancer and endometrial cancer. The treatment of the patient because of the metastatic cancer was started after the histopathological diagnosis. In metastatic lymph node the endometrial cancer was recognized. The carboplatin and paclitaxel were used in the therapy. The treatment was conducted in four course chemotherapy. It revealed considerable polyneuropathy and hematologic toxicity limiting from further therapy. Treatment allowed to obtain biochemical response, decrease of metastases and the condition of a patient improved. During the systemic therapy thromboprophylaxis with acenocumarol was used. The incidence of venous thromboembolism or bleeding complications were not noticed.

4

Prognostic value of neurotrophic growth factor (BDNF) in patients with colorectal cancer during chemotherapy

61%

Olborska M. , Głogowska-Gruszka A. , Słomian G. , Buczkowska M. , Szkilnik R. , Nowak P.

Annales Academiae Medicae Silesiensis

|

2019

|

nr 73

283-292

EN

INTRODUCTION: The brain-derived neurotrophic factor (BDNF) is a protein belonging to neurotrophins that plays a key role in the proper development and functioning of the mammalian central nervous system. Previous studies have focused on assessment of the BDNF concentration in blood serum as a potential biomarker in neurological disorders. Recently, the BDNF signalling pathway has been recognised as a potential target for anticancer drugs, while its receptor (TrkB) as an oncogene in colorectal cancer cells. Despite the significant role in carcinogenesis, there are few studies on BDNF as a biomarker in colorectal cancer. MATERIAL AND METHODS: The study included 25 patients with clinically and histopathologically confirmed colorectal cancer, who were qualified for treatment. Prior to the first administration of chemotherapy, venous blood samples were collected from the patients and the biochemical parameters routinely determined prior to treatment were evaluated. Additionally, the serum BDNF concentration was determined by the immunoenzymatic method in all the patients. RESULTS: The serum BDNF concentration in patients was 50.24 ± 23.37 ng/ml. The BDNF concentration did not differ significantly between women and men. A negative correlation was found between the BDNF and CRP concentration and the BDNF and LDH concentration. The BDNF levels were significantly higher in patients who underwent primary tumour resection before chemotherapy. There was no correlation between the BDNF concentration and age, gender, BMI, CEA marker and liver enzymes in patients with colorectal cancer. There was no correlation between the BDNF concentration and clinical response to the treatment. CONCLUSIONS: BDNF cannot be considered as a prognostic factor in patients with colorectal cancer.

PL

WSTĘP: Neurotropowy czynnik pochodzenia mózgowego (Brain-Derived Neutortophic Factor – BDNF) jest białkiem należącym do rodziny neurotrofin, które odgrywa kluczową rolę w prawidłowym rozwoju i funkcjonowaniu ośrodkowego układu nerwowego ssaków. Dotychczasowe badania dotyczyły głównie oceny stężenia BDNF w surowicy krwi, jako potencjalnego biomarkera w schorzeniach neurologicznych. Ostatnio ścieżka sygnałowa BDNF uznana została za potencjalne miejsce uchwytu leków przeciwnowotworowych, a jego receptor (TrkB) za onkogen w komórkach raka jelita grubego. Pomimo znaczącej roli w nowotworzeniu, niewiele jest prac dotyczących BDNF jako biomarkera w raku jelita grubego. MATERIAŁ I METODY: Badaniem objęto grupę 25 osób z potwierdzonym klinicznie i histopatologicznie rakiem jelita grubego, którzy zostali zakwalifikowani do leczenia. Przed pierwszorazowym podaniem chemioterapii od pacjentów pobrano próbki krwi żylnej i dokonano oceny parametrów biochemicznych oznaczanych rutynowo przed leczeniem. Dodatkowo metodą immunoenzymatyczną oznaczono stężenia BDNF w surowicy krwi wszystkich badanych pacjentów. WYNIKI: Stężenie BDNF w surowicy pacjentów wyniosło 50,24 ± 23,37 ng/ml i nie różniło się istotnie pomiędzy kobietami i mężczyznami. Stwierdzono ujemną korelację między stężeniem BDNF i CRP oraz BDNF i LDH. Stężenie BDNF było znamiennie wyższe u chorych, którzy przed chemioterapią byli poddani resekcji guza pierwotnego. Nie wykazano zależności pomiędzy stężeniem BDNF a wiekiem, płcią, wskaźnikiem BMI, markerem CEA oraz enzymami wskaźnikowymi wątroby u pacjentów z RJG. Nie zaobserwowano zależności pomiędzy stężeniem BDNF a odpowiedzią kliniczną na zastosowane leczenie. wnioski: BDNF nie może być uznany za czynnik prognostyczny u chorych z rakiem jelita grubego.